Hyperthermia as a Potential Cornerstone of Effective Multimodality Treatment with Radiotherapy, Cisplatin and PARP Inhibitor in <i>IDH1</i>-Mutated Cancer Cells
Mutations in the isocitrate dehydrogenase 1 (<i>IDH1</i><sup>MUT</sup>) gene occur in various types of malignancies, including ~60% of chondrosarcomas, ~30% of intrahepatic cholangiocarcinomas and >80% of low-grade gliomas. <i>IDH1</i><sup>MUT</sup>...
Main Authors: | Mohammed Khurshed, Elia Prades-Sagarra, Sarah Saleh, Peter Sminia, Johanna W. Wilmink, Remco J. Molenaar, Hans Crezee, Cornelis J. F. van Noorden |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/24/6228 |
Similar Items
-
<i>IDH1</i> Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
by: Fabiana Crispo, et al.
Published: (2020-08-01) -
<i>IDH</i> Mutations in Chondrosarcoma: Case Closed or Not?
by: Sanne Venneker, et al.
Published: (2023-07-01) -
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
by: Georgios Solomou, et al.
Published: (2023-05-01) -
Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
by: Makoto Nakagawa, et al.
Published: (2022-06-01) -
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with <i>IDH1</i>-Mutated Solid Tumors
by: Mohammed Khurshed, et al.
Published: (2021-05-01)